NEW YORK--(BUSINESS WIRE)--ImClone Systems Incorporated (NASDAQ: IMCL) today announced that the first of its disease-directed clinical trials of IMC-11F8, a potent fully human IgG1 monoclonal antibody to the epidermal growth factor receptor (EGFR), has commenced patient enrollment. This open label, multicenter European Phase II study of IMC-11F8 is enrolling patients with treatment-naïve locally-advanced or metastatic colorectal cancer. A total of 40 patients are expected to be enrolled. This Phase II study is designed to evaluate the efficacy and safety of IMC-11F8 administered every two weeks by intravenous infusion in combination with mFOLFOX-6 (5-FU/FA/oxaliplatin) therapy.
